<p>(A) Spleen GC level in 4L;C* mice was not different from that in the WT. GS level was accumulated in 4L;C* spleen. By 600 mg/kg/d IFG treatment, GC or GS were increased by 2-fold in 4L;C* spleen at 14 day or 28 day, respectively. (B) GC and GS were accumulated in 4L;C* lung. IFG treatment did not reduce the substrate level in 4L;C* lung. Increased GC level was in 600 mg/kg/d IFG treated lung at terminal stage (Age was same as spleen in Fig. 5A). The data represent the mean±S.E. and analyzed by Student's t-test. *, p<0.05 (n = 3 mice). The GC and GS levels were normalized by tissue weight.</p
<p>(A) Tissue expression of GCStg protein. Frozen liver sections from WT (<i>Ugcg+/+</i>) (upper pan...
<p>(A) Mice (n = 12/group) were infected i.n. with 10<sup>4</sup> PFU of V<sub>K627</sub> (▪), rV<su...
<p>A. Brightfield microscopy of representative spleen sections from day 9 and 30 sRBC immunized WT a...
<p>(A) Cortex GC and GS levels in IFG treated 4L;C* did not show significant reduction relative to t...
<p>Total GC levels in liver, lung, and spleen from 9V/null (red), 9H/9H (violet), 9V/9V (green), and...
<p>(A) GlcCer concentration in visceral tissues. The lungs, livers and spleens from 9-, 18-, 28- and...
<p>The graphs contain the GC values (mean ± SE) from 7–16 mice in each dosing cohort relative to the...
<p>(A) The mean proportion of each GC species relative to total GC (6 GC species) in age-matched <i>...
<p>The fold changes of GC species and glucosylsphingosine levels in individual mutant mice were age-...
<p>Each panel presents GC species levels in mice having the indicated <i>Gba1</i> mutation: D409H (9...
<p>GC species in the spleen (9H/9H, 9H;C*, 4L/4L, 4L;C*, 9V/9V, and 9V/null), whole brain (9H;C*, 4L...
<p>(A) GCase activity was significantly increased in the treated 4L;C* liver by 3-fold in 20 mg/kg/d...
<p>Total GSH (A) and GSSG (B) in BALF and total GSH (C) and GSSG (D) in the lungs at the indicated t...
<p>(A) Tissue GlcCer species in the lungs, livers, spleens and brains from 9-wk of WT, WT+GCStg, 9V/...
<p><b>(A)</b> DC and B cell numbers in blood collected from B16 melanoma-bearing mice treated daily ...
<p>(A) Tissue expression of GCStg protein. Frozen liver sections from WT (<i>Ugcg+/+</i>) (upper pan...
<p>(A) Mice (n = 12/group) were infected i.n. with 10<sup>4</sup> PFU of V<sub>K627</sub> (▪), rV<su...
<p>A. Brightfield microscopy of representative spleen sections from day 9 and 30 sRBC immunized WT a...
<p>(A) Cortex GC and GS levels in IFG treated 4L;C* did not show significant reduction relative to t...
<p>Total GC levels in liver, lung, and spleen from 9V/null (red), 9H/9H (violet), 9V/9V (green), and...
<p>(A) GlcCer concentration in visceral tissues. The lungs, livers and spleens from 9-, 18-, 28- and...
<p>The graphs contain the GC values (mean ± SE) from 7–16 mice in each dosing cohort relative to the...
<p>(A) The mean proportion of each GC species relative to total GC (6 GC species) in age-matched <i>...
<p>The fold changes of GC species and glucosylsphingosine levels in individual mutant mice were age-...
<p>Each panel presents GC species levels in mice having the indicated <i>Gba1</i> mutation: D409H (9...
<p>GC species in the spleen (9H/9H, 9H;C*, 4L/4L, 4L;C*, 9V/9V, and 9V/null), whole brain (9H;C*, 4L...
<p>(A) GCase activity was significantly increased in the treated 4L;C* liver by 3-fold in 20 mg/kg/d...
<p>Total GSH (A) and GSSG (B) in BALF and total GSH (C) and GSSG (D) in the lungs at the indicated t...
<p>(A) Tissue GlcCer species in the lungs, livers, spleens and brains from 9-wk of WT, WT+GCStg, 9V/...
<p><b>(A)</b> DC and B cell numbers in blood collected from B16 melanoma-bearing mice treated daily ...
<p>(A) Tissue expression of GCStg protein. Frozen liver sections from WT (<i>Ugcg+/+</i>) (upper pan...
<p>(A) Mice (n = 12/group) were infected i.n. with 10<sup>4</sup> PFU of V<sub>K627</sub> (▪), rV<su...
<p>A. Brightfield microscopy of representative spleen sections from day 9 and 30 sRBC immunized WT a...